Donanemab for Treatment of Alzheimer’s Disease

EP: 1.Presentation of Alzheimer’s Disease in Clinical Practice

EP: 2.Diagnosis and Treatment of Alzheimer’s Disease

EP: 3.Lecanemab for Treatment of Early Alzheimer Disease

EP: 4.ARIA With Monoclonal Antibody Treatments for Alzheimer Disease

EP: 5.Clarity-AD-OLE Study in Alzheimer’s Disease

EP: 6.Continuous Dosing of Lecanemab for Alzheimer’s Disease

Now Viewing

EP: 7.Donanemab for Treatment of Alzheimer’s Disease

EP: 8.Biomarkers in Alzheimer’s Disease (May 2025)

EP: 9.Emerging Agents in Alzheimer’s Disease

Summary for Physicians

TRAILBLAZER-ALZ-2 Clinical Trial: Donanemab in Early Alzheimer’s Disease

Trial Design:

• Objective: The TRAILBLAZER-ALZ-2 trial investigated donanemab, a monoclonal antibody targeting amyloid-beta plaques, specifically binding to soluble and insoluble forms of amyloid to promote their removal. It aimed to assess efficacy and safety in patients with early symptomatic Alzheimer’s disease.
• Population: Participants were early Alzheimer’s patients with mild cognitive impairment (MCI) or mild dementia, and evidence of amyloid plaque on imaging.
• Methodology:
  • Randomized, double-blind, placebo-controlled design.
  • Patients were administered donanemab (700 mg every 4 weeks) or placebo for 18 months.
  • The primary endpoint was cognitive decline measured by the ADAS-Cog14 (Alzheimer’s Disease Assessment Scale-Cognitive Subscale).
  • Secondary endpoints included functional decline (measured by CDR-SB), and biomarker analysis (amyloid plaque burden, tau levels, and neurodegeneration markers).

Study Results:

• Efficacy:
  • Donanemab significantly reduced amyloid plaque in treated patients, with rapid plaque removal seen within months of initiating therapy.
  • Cognitive Outcomes: Treatment with donanemab led to slower cognitive decline compared to placebo, as measured by ADAS-Cog14 and CDR-SB. The magnitude of effect was similar to that seen with other amyloid-targeting therapies, though donanemab had a slightly higher rate of amyloid clearance.
  • Functional Impact: The trial showed a significant benefit in functional outcomes as well, with patients on donanemab demonstrating slower progression of activities of daily living compared to those on placebo.
• Safety:
  • ARIA (Amyloid-Related Imaging Abnormalities) were reported, similar to other amyloid-modifying therapies, but occurred in a manageable proportion of patients.
  • Adverse Events: Most adverse events were mild to moderate, with no new significant safety concerns emerging beyond those seen in earlier amyloid-modifying trials (e.g., lecanemab).
  • Discontinuation Rates: Discontinuations due to side effects were relatively low, with most patients tolerating the therapy with appropriate monitoring.

Clinical Implications:

• Donanemab shows potential as an effective disease-modifying treatment for patients with early-stage Alzheimer’s disease, significantly reducing amyloid plaques and slowing cognitive and functional decline.
• ARIA management remains essential, requiring regular MRI monitoring for early detection of side effects.
• The results are comparable to those seen with other amyloid-targeting antibodies (like lecanemab), but donanemab's faster amyloid plaque reduction could offer clinical advantages in slowing disease progression.